This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check. Eli Lilly’s Mounjaro (tirzepatide) was given the green light by the US Food and Drug Administration after the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 glucagon-like peptide-1 (GLP-1 ) receptor agonist showed its effectiveness when used in conjunction with diet and exercise.
The companyâs analysis of 2.5m patients worldwide suggest a growing proportion of younger patients, with implications for future study design and deployment.
A digital health startup accelerator is launching in Italy, with more than €6 million backing the new enterprise. Called VITA, the accelerator will support up to 10 startups focused on digital transformation of the health system. The project is backed by asset management company CDP Venture Capital SGR, with help from digital health consultancy Healthware Group (pharmaphorum’s parent company) and Danish accelerator Accelerace.
We have all been at various points in our lives where we felt we have had enough and desired a change. It could be breaking free from an addiction, deciding to start a family, or in this case leaving a job where you have been unhappy and stressed. However, a few days or weeks down the line, we end up not following our action plan or even fail to draft out one.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial results announced by AstraZeneca and Avillion. Asthma affects as many as 339 million adults and children around the world. Regardless of severity, the condition means that these patients are at risk of severe exacerbations, with an estimated 176 million asthma exacerbations globally per year.
The cancer trial-matching company is partnering with MPN Research Foundation to help match patients with a group of rare blood cancers to clinical trials.
Adele Waugaman, senior digital health coordinator of the COVID-19 response at the United States Agency for International Development (USAID), tells us what the agency focuses on to strengthen digital health infrastructure globally and improve and expand healthcare access. USAID learned a great deal from the Ebola outbreak in West Africa concerning effective digital health distribution and strategies for digital health implementation that were then applied to its COVID-19 response globally – alth
An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator. Inmagene Pharma’s investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor, can now proceed to a phase 1 clinical trial, following the green light from the US Food and Drug Administration.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
115 
Let's personalize your content